[HTML][HTML] Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation
JCH Yang, SM Gadgeel, LVD Sequist, CL Wu… - Journal of Thoracic …, 2019 - Elsevier
Introduction Anti-EGFR agents are standard treatments for patients with EGFR-mutant
advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti …
advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti …
[HTML][HTML] Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC
S Gettinger, MD Hellmann, LQM Chow… - Journal of Thoracic …, 2018 - Elsevier
Introduction This phase I study evaluated nivolumab combined with erlotinib in patients with
advanced EGFR-mutant NSCLC. Methods Patients with advanced EGFR-mutant NSCLC …
advanced EGFR-mutant NSCLC. Methods Patients with advanced EGFR-mutant NSCLC …
[HTML][HTML] A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation–positive …
G Scagliotti, D Moro-Sibilot, J Kollmeier… - Journal of Thoracic …, 2020 - Elsevier
Introduction The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET)
is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in …
is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in …
[HTML][HTML] Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter …
MC Piccirillo, L Bonanno, MC Garassino… - Journal of Thoracic …, 2022 - Elsevier
Introduction Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
[HTML][HTML] A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC
A Lisberg, A Cummings, JW Goldman… - Journal of Thoracic …, 2018 - Elsevier
Background Despite the significant antitumor activity of pembrolizumab in NSCLC, clinical
benefit has been less frequently observed in patients whose tumors harbor EGFR mutations …
benefit has been less frequently observed in patients whose tumors harbor EGFR mutations …
Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
Y Chen, Z Yang, Y Wang, M Hu, B Zhang… - Frontiers in …, 2021 - frontiersin.org
Objectives More and more encouraging evidence revealed that immunotherapy could
improve clinical outcomes in patients with previously treated non-small cell lung cancer …
improve clinical outcomes in patients with previously treated non-small cell lung cancer …
Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) …
NA Rizvi, LQM Chow, H Borghaei, Y Shen, C Harbison… - 2014 - ascopubs.org
8022 Background: Erlotinib is FDA-approved for the first-line treatment of EGFR MT NSCLC,
with a median progression free survival (PFS) of 10.4 months. Nivolumab, a fully human …
with a median progression free survival (PFS) of 10.4 months. Nivolumab, a fully human …
441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
Background Erlotinib (E) targeted therapy in EGFR mutant non-small cell lung cancer
(NSCLC) can effectively reduce tumor burden; however, the durability of response is limited …
(NSCLC) can effectively reduce tumor burden; however, the durability of response is limited …
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - 2018 - ascopubs.org
9007 Background: In JO25567 (Clinical trials registry number. JapicCTI-111390), EB
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …
NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
M Maemondo, T Fukuhara, H Saito, N Furuya… - 2020 - ascopubs.org
9506 Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …